Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
Completed · Phase 1
Conditions studied: Malignancies
In brief
The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are to assess preliminary anti-tumor activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as measured by objective response rate (ORR).
Key facts
- Study ID
- NCT03005782
- Run by
- Regeneron Pharmaceuticals
- People needed
- 333
- Starts
- 2016-11-07
- Expected to finish
- 2024-04-02
- Last updated by the study team
- 2024-05-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- California Cancer Associates for Research and Excellence — Encinitas, California, United States
- California Cancer Associates For Research And Excellence — Fresno, California, United States
- University of California San Diego (UCSD) — La Jolla, California, United States
- The Angeles Clinic — Los Angeles, California, United States
- University of California Davis Health Systems — Sacramento, California, United States
- California Pacific Medical Center (CPMC) — San Francisco, California, United States
- University of Colorado Cancer Center — Aurora, Colorado, United States
- Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital — Washington D.C., District of Columbia, United States
- Miami Cancer Institute — Miami, Florida, United States
- Orlando Health, Inc — Orlando, Florida, United States
- Winship Cancer Institute at Emory University — Atlanta, Georgia, United States
- University of Kansas Clinical Research Center — Fairway, Kansas, United States
- Dana Farber Cancer Institute — Jamaica Plain, Massachusetts, United States
- Henry Ford Health Hospital — Detroit, Michigan, United States
- Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan, United States
- Washington University in Saint Louis — St Louis, Missouri, United States
- John Theurer Cancer Center, Hackensack University Medical Center — Hackensack, New Jersey, United States
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- New Mexico Cancer Care Alliance-UNM Cancer Center — Albuquerque, New Mexico, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Northwell Health-Monter Cancer Center — Lake Success, New York, United States
- Laura & Isaac Perlmutter Cancer Center — New York, New York, United States
- Columbia University — New York, New York, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Levine Cancer Institute — Charlotte, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.